Retractable Technologies, Inc. (NYSE:RVP – Get Free Report) CEO Thomas J. Shaw purchased 12,445 shares of Retractable Technologies stock in a transaction on Monday, January 27th. The shares were acquired at an average price of $0.81 per share, with a total value of $10,080.45. Following the transaction, the chief executive officer now directly owns 15,019,308 shares in the company, valued at $12,165,639.48. This trade represents a 0.08 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Retractable Technologies Price Performance
Retractable Technologies stock opened at $0.84 on Friday. The company’s fifty day moving average price is $0.69 and its two-hundred day moving average price is $0.81. Retractable Technologies, Inc. has a one year low of $0.56 and a one year high of $1.34. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.57 and a quick ratio of 5.92.
Wall Street Analysts Forecast Growth
Separately, StockNews.com began coverage on shares of Retractable Technologies in a research note on Thursday. They set a “hold” rating on the stock.
Institutional Trading of Retractable Technologies
A hedge fund recently bought a new stake in Retractable Technologies stock. PFG Investments LLC purchased a new stake in Retractable Technologies, Inc. (NYSE:RVP – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 34,600 shares of the company’s stock, valued at approximately $27,000. PFG Investments LLC owned approximately 0.12% of Retractable Technologies at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.58% of the company’s stock.
Retractable Technologies Company Profile
Retractable Technologies, Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes.
Further Reading
- Five stocks we like better than Retractable Technologies
- With Risk Tolerance, One Size Does Not Fit All
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Are Penny Stocks a Good Fit for Your Portfolio?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Retractable Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retractable Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
